NDA 021829 · Ucb INC
Neupro
Rotigotine · Transdermal · Nonergot Dopamine Agonist
NovelLast checked: Nov 20, 2026Latest source record: Jul 12, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
May 9, 2007
Approved uses
3
Original approval plus efficacy supplements
Registered trials
95
34 Phase 3, 2 recruiting
FAERS reports
14,738
9,295 serious, 2,175 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 11, 2026.
NEUPRO is a dopamine agonist indicated for the treatment of: Parkinson's disease ( 1.1 ) Moderate-to-severe primary Restless Legs Syndrome ( 1.2 ) 1.1 Parkinson's Disease (PD) NEUPRO is indicated for the treatment of Parkinson's disease. 1.2 Restless Legs Syndrome (RLS) NEUPRO is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome.
Mechanism: Rotigotine is a non-ergoline dopamine agonist. The precise mechanism of action of rotigotine as a treatment for Parkinson's disease is unknown, although it is thought to be related to its ability to stimulate dopamine receptors within the caudate-putamen in the brain. The precise mechanism of action of rotigotine as a treatment for Restless Legs Syndrome is unknown but is thought to be related to its ability to stimulate dopamine receptors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 2, 2012 Supplement 2 · Efficacy LabelReviewLetter
- Apr 2, 2012 Supplement 1 · Efficacy ReviewLetterLabel
- May 9, 2007 Original approval · Type 1 - New Molecular Entity NovelLabelReviewPatient Package Insert
6 products under this application
- NEUPRO · ROTIGOTINE 1MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
- NEUPRO · ROTIGOTINE 4MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
- NEUPRO · ROTIGOTINE 3MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
- NEUPRO · ROTIGOTINE 6MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
- NEUPRO · ROTIGOTINE 2MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
- NEUPRO · ROTIGOTINE 8MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Rotigotine" as an intervention, any sponsor and status, largest first.
- Quality Improvement and Practice Based Research in Neurology Using the EMREnrolling by invitation
Endeavor HealthAcademic, hospital or other
NCT02670161 · 3,300 participants (planned) · Start May 2016 · Primary completion Dec 2026
Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) · For: Brain Tumors; Epilepsy; Migraine and 7 more
Sites: Evanston, Illinois
- Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs SyndromePivotal-lookingCompleted
UCB PharmaUCB
NCT00135993 · 811 participants · Start May 2005 · Primary completion Nov 2006
Drug: Rotigotine · For: Restless Legs Syndrome
Sites: RTP, North Carolina
- Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg SyndromePivotal-lookingCompleted
UCB PharmaUCB
NCT00136045 · 549 participants · Start May 2005 · Primary completion Aug 2006
Drug: Rotigotine · For: Restless Legs Syndrome
Sites: Monheim, Germany
- Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal PatchPivotal-lookingCompleted
UCB PharmaUCB
NCT00522379 · 514 participants · Start Jul 2007 · Primary completion Jul 2011
Drug: Rotigotine; Rotigotine and 2 more · For: Parkinson's Disease
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Gilbert, Arizona · 77 sites in all
- Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on LevodopaPivotal-lookingCompleted
UCB PharmaUCB
NCT00244387 · 506 participants · Start Mar 2004 · Primary completion Jul 2005
Drug: SPM 962 · For: Parkinson Disease, Idiopathic
Sites: Monheim, Germany
- An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's DiseasePivotal-lookingCompleted
UCB PharmaUCB
NCT00501969 · 395 participants · Start Aug 2004 · Primary completion Dec 2008
Drug: Rotigotine · For: Advanced Stage Parkinson's Disease
Sites: Bedford Park, Australia; Concord, Australia; Darlinghurst, Australia · 53 sites in all
- An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's DiseasePivotal-lookingCompleted
UCB PharmaUCB
NCT00599196 · 381 participants · Start Aug 2002 · Primary completion Dec 2008
Drug: Rotigotine · For: Early Stage Parkinson's Disease
Sites: Concord, Australia; Darlinghurst, Australia; East Gosford, Australia · 63 sites in all
- Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease PatientsPivotal-lookingCompleted
NCT01523301 · 380 participants · Start Apr 2012 · Primary completion Oct 2014
Drug: Rotigotine; Placebo · For: Idiopathic Parkinson's Disease
Sites: Ansan, South Korea; Anyang, South Korea; Busan, South Korea · 29 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product adhesion issue1,963
- drug ineffective1,171
- fall1,013
- death984
- off label use922
- parkinson^s disease800
- hallucination771
- dyskinesia698
- tremor655
- nausea555
- dizziness523
- somnolence477
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 128 |
| 2008 | 603 |
| 2009 | 126 |
| 2010 | 131 |
| 2011 | 129 |
| 2012 | 170 |
| 2013 | 260 |
| 2014 | 302 |
| 2015 | 471 |
| 2016 | 820 |
| 2017 | 917 |
| 2018 | 866 |
| 2019 | 1,295 |
| 2020 | 1,207 |
| 2021 | 1,579 |
| 2022 | 1,461 |
| 2023 | 1,098 |
| 2024 | 1,164 |
| 2025 | 1,075 |
| 2026 | 936 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Neupro (Rotigotine)
2024 spending
$90.1M
Beneficiaries
14,920
77,655 claims
Per beneficiary
$6,037
$27.60 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $95,138,638 |
| 2021 | $94,625,403 |
| 2022 | $96,535,024 |
| 2023 | $92,722,198 |
| 2024 | $90,068,151 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis.
Stinton C, McKeith I, Taylor JP, et al. · Am J Psychiatry 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Restless Legs Syndrome in Chronic Kidney Disease- a Systematic Review.
Safarpour Y, Vaziri ND, Jabbari B · Tremor Other Hyperkinet Mov (N Y) 2023 · Systematic Review
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Implications of dopaminergic medication withdrawal in Parkinson's disease.
Koschel J, Ray Chaudhuri K, Tönges L, et al. · J Neural Transm (Vienna) 2022 · Systematic Review
- Transdermal rotigotine for the perioperative management of Parkinson's disease.
Wüllner U, Kassubek J, Odin P, et al. · J Neural Transm (Vienna) 2010 · Clinical Trial, Multicenter Study
- Adverse effects produced by different drugs used in the treatment of Parkinson's disease: A mixed treatment comparison.
Li BD, Bi ZY, Liu JF, et al. · CNS Neurosci Ther 2017 · Comparative Study, Meta-Analysis
Sponsor: UCB
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.